Aug 4, 2005 by Charly TraversThis One's a WinnerEncysive awaits FDA approval, and all signs are positive.
Aug 3, 2005 by Charly TraversBiotech's Big DealThe market is pleased with the partnership between Protein Design Labs and Biogen IDEC.
Aug 2, 2005 by Charly TraversEarn More by Doing LessPatience is as important as foresight in your hunt for rule-breaking returns.
Jul 26, 2005 by Charly TraversFor Shame, Warburg PincusDirectors are supposed to represent the interests of all shareholders -- not just the biggest.
Jul 25, 2005 by Charly TraversTranskaryotic Therapies: What's It Worth?Charly Travers thinks shareholders will be shortchanged by the company's upcoming merger.
Jul 21, 2005 by Charly TraversThwarting the Big Bad WolfDoes your company have a sustainable moat to ward off upstart competitors?
Jul 14, 2005 by Charly TraversDueling Fools: Protein Design Labs BullCharly Travers and Stephen Simpson square off over this biotech's true value.
Jul 14, 2005 by Charly TraversDueling Fools: Protein Design Labs Bull RebuttalThis biotech's tomorrow is coming today.
Jul 12, 2005 by Charly TraversGenentech Shines OnThe world's largest biotech has been a four-bagger since 2003. Is it too late to get in the game?
Jun 28, 2005 by Charly TraversGrowth Around the Corner?Despite a thin pipeline, one small biotech is hoping to ride the wave of prosperity.
Jun 21, 2005 by Charly TraversA Biotech BargainPaying $1.6 billion for a robust pipeline and promising future may be a steal.
Jun 15, 2005 by Charly TraversFlamel's CEO Must GoFlamel's shareholders must vote to remove a management road block to the company's success.
May 27, 2005 by Charly TraversVertex's Cautious OptimismThe company's innovative hepatitis C drug has made May a month to remember.
May 24, 2005 by Charly TraversGenentech Eyes a New MarketWill Lucentis be the next addition to the biotech giant's growing drug portfolio?
May 17, 2005 by Charly TraversBioMarin Bounces BackAfter a stumble, one biotech firm is returning to the market's good graces.
May 10, 2005 by Charly TraversDendreon in the SpotlightProstate cancer drug on display at a cancer meeting.
May 10, 2005 by Charly TraversThe Future of Cancer TherapyOne biotech is blazing a trail for long-term success. Should investors take notice?
May 5, 2005 by Charly TraversOSI's Cancer BlockbusterTarceva will turn OSI Pharmaceuticals into a leading biotech.
May 3, 2005 by Charly TraversPDL's Well-Stocked PipelineA broad drug portfolio makes this biotech a long-term winner.
